BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults

Reuters

2024/12/13

Dec 13 (Reuters) - EMA'S CHMP:

EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITY
EMA'S CHMP: SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJARO
EMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)
EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINION
EMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIA
EMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)

Source text: [ID:]

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2491326161"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491326161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491326161?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491326161","market":"us","top_or_hot":-1,"title":"BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults</title></head><body><p><span>Dec 13 (Reuters)</span><span> - </span>EMA'S CHMP: </p><ul><li><p>EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITY</p></li><li><p>EMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJARO</p></li><li><p>EMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)</p></li><li><p>EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINION</p></li><li><p>EMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIA</p></li><li><p>EMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-12-13 19:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults</title></head><body><p><span>Dec 13 (Reuters)</span><span> - </span>EMA'S CHMP: </p><ul><li><p>EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITY</p></li><li><p>EMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJARO</p></li><li><p>EMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)</p></li><li><p>EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINION</p></li><li><p>EMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIA</p></li><li><p>EMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237438978.USD","symbol_name":"Amundi Funds US Pioneer A2 (C) USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0F2:1","article_id":"2491326161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491326161","pubTimestamp":1734090488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese AdultsDec 13  - EMA'S CHMP: EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITYEMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJAROEMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA EMA'S CHMP: KAVIGALE  RECEIVED POSITIVE OPINIONEMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIAEMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG Source text: [ID:]Further company coverage: LLY.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK5011":"制药","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","MRK":"默沙东","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BBIO":"BridgeBio Pharma, Inc.","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","GERN":"杰龙","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","AZN.UK":"阿斯利康制药","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","03165":"华夏欧优股对冲","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0097036916.USD":"贝莱德美国增长A2 USD","LLY":"礼来","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC"},"translate_title":"简介-EMA的CHMP表示肥胖成人OSA无需单独使用Mounjaro适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9,"03165":0.6,"MRK":0.9,"AZN.UK":0.9,"LLY":0.9,"GERN":0.9},"content_text":"BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese AdultsDec 13 (Reuters) - EMA'S CHMP: EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITYEMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJAROEMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINIONEMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIAEMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)Source text: [ID:]Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}